BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2286709)

  • 1. Haloperidol plasma levels and acute clinical change in schizophrenia.
    Coryell W; Kelly M; Perry PJ; Miller DD
    J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma drug level and clinical response.
    Cooper TB; Volavka J; Czobor P
    J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036
    [No Abstract]   [Full Text] [Related]  

  • 18. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
    Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.